Lantern Pharma Inc. (LTRN) - Form 8-K Summary
Business Context and Reporting Period
Lantern Pharma Inc., a Delaware corporation, filed this Current Report on Form 8-K on May 15, 2026. The filing announces the release of financial results for the first quarter ended March 31, 2026. The company's common stock trades on The Nasdaq Stock Market under the symbol LTRN.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document serves as a notification that a press release containing these details (Exhibit 99.1) has been issued, but the numerical data is not embedded within the 8-K text itself.
Material Changes
No material changes versus the prior comparable period are detailed in this filing. The document references an external press release for the comparative financial analysis.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. It explicitly states that the information in Item 2.02 and the attached press release is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 15, 2026) for actual Q1 2026 financial figures.
- Verify the company's cash position and burn rate in the full press release, as this 8-K does not disclose liquidity metrics.
- Check for any updated clinical trial milestones or regulatory developments mentioned in the press release.
- Confirm the status of the company's debt obligations and working capital in the detailed financial statements referenced.